The β blockers: Are they as protective in hypertension as in other cardiovascular conditions?

Journal of Clinical Hypertension

Volumn 3, Issue 4, 2001, Pages 236-243

  Hanes, D S ^a   Weir, M R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESMOLOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LABETALOL; METOPROLOL; NADOLOL; PROPRANOLOL; RENIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ARTICLE; CARDIOSELECTIVITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; ELDERLY CARE; GLUCOSE TOLERANCE; HEART INFARCTION; HEART OUTPUT; HEART RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPID SOLUBILITY; METABOLIC DISORDER; MORTALITY; PRESCRIPTION; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 0034889097     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2001.00444.x     Document Type: Article

References (37)

1. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US: Population data from the health examination surveys, 1960 to 1991
2. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
3. Trends in antihypertensive drug use in the United States. Do the JNC V recommendations affect prescribing?
4. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomized trial
5. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes. UKPDS 38
6. Beta-blockers in the treatment of hypertension
7. Beta blockade during and after myocardial infarction: An overview of the randomized trials
8. Chronopharmacology and chronotherapy of cardiovascular medication: Relevance to prevention and treatment of coronary heart disease
9. Left ventricular hypertrophy and its regression: Pathophysiology and therapeutic approach
10. Carvedilol update: A multiple action antihypertensive agent with antioxidant capacity and the potential for myocardial and vascular protection
11. Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and the effects of celiprolol
12. Heart rate as a cardiovascular risk factor
13. Heart rate and cardiovascular mortality: The Framingham Study
14. Beta-blockers blunt the morning surge in blood pressure and heart rate
15. Randomized double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
16. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?
17. Beta-blockers and diuretics: To use or not to use
18. Medical Research Council trial of treatment of hypertension in older adults: Principle results
19. Treatment with beta-blockers for the primary prevention of the cardiovascular complications of hypertension
20. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension
21. The place for beta-blockers in treating hypertension
22. Early beta-blocker therapy for acute myocardial infarction in elderly patients
23. Antihypertensive therapy and insulin sensitivity: Do we have to redefine the role of beta-blocking agents?
24. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus
25. The effects of cardiovascular drugs on plasma lipids and lipoproteins
26. Diuretics and beta blockers: Is there a risk for hyperlipidemia?
27. Low mortality from all causes, including myocardial infarction, in wellcontrolled hypertensives treated with beta-blockers plus other antihypertensives
28. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan
29. Prevention of sudden cardiac death with beta-blockers
30. Heart rate dynamics at the onset of ventricular tachyarrhythmias as retrieved from implantable cardioverter-defibrillators in patients with coronary artery disease
31. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
32. Drug therapy before coronary artery surgery: Nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival
33. Beta-blockers: The new standard of therapy for mild heart failure
34. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
35. Effects of controlled-release metoprolol of total mortality, hospitalizations, and well-being in patients with heart failure: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
36. Possible mechanisms of action in the positive effect of beta-blockers in heart failure
37. ACE inhibitor and beta-blocker use in CHF outpatients: Are we translating clinical trials into practice?